Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

Antengene to Present First Preclinical Data on ATG-207 (αCD3-TGF-β Bifunctional Fusion Protein) at EULAR 2026

SHANGHAI and HONG KONG, June 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for the treatment of cancer and autoimmune diseases, has announced that it will present its first preclinical data on ATG-207, a bifunctional fusion protein targeting CD3 and TGF-β, at the upcoming European League Against Rheumatism (EULAR) 2026 conference.

Overview of ATG-207

ATG-207 represents a novel approach in the treatment landscape, combining the mechanisms of action targeting T cells and modulating the TGF-β pathway. This innovative fusion protein aims to enhance anti-tumor immunity while concurrently addressing the immunosuppressive environment often found in chronic diseases. The preclinical data set to be shared at EULAR is expected to showcase the promising efficacy and safety profile of ATG-207, highlighting its potential as a game-changer in therapeutic strategies.

Importance of EULAR 2026

The EULAR conference is one of the most prestigious gatherings in the field of rheumatology, bringing together leading researchers, clinicians, and industry professionals from around the globe. The platform provides a unique opportunity for companies like Antengene to share groundbreaking research and innovations. Presenting at such an event not only enhances visibility but also facilitates crucial discussions on the future of treatments in autoimmune diseases. The insights gained from peer interactions during the conference could prove invaluable in shaping the next steps in the development of ATG-207.

Antengene's Commitment to Innovation

Antengene’s commitment to advancing medical science is evident in its robust pipeline of therapies targeting various malignancies and autoimmune conditions. With a focus on first-in-class and best-in-class drug development, the company employs cutting-edge technologies and a patient-centric approach to research. ATG-207 is a testament to this commitment, as it embodies Antengene's vision of addressing unmet medical needs through innovative solutions.

Potential Impact on Patients

The introduction of ATG-207 could significantly impact patients suffering from chronic autoimmune diseases and certain cancers. By targeting both the CD3 protein on T cells and the TGF-β pathway, the therapy aims to activate the immune system while simultaneously preventing the suppression that often complicates treatment efficacy. This dual mechanism may lead to improved patient outcomes, reduced disease progression, and a better overall quality of life for those affected by such conditions.

Future Directions

As Antengene prepares for its presentation at EULAR 2026, the company is also looking ahead to potential clinical trials and further research studies to validate the findings from the preclinical data. Engaging with the scientific community and gathering feedback will be crucial in refining the development strategy for ATG-207. The insights from EULAR could pave the way for collaborations, partnerships, and potentially accelerated pathways for clinical approvals.

Conclusion

Antengene's presentation of ATG-207 at EULAR 2026 marks a significant milestone in the realm of biotechnology and therapeutic innovation. As the company continues to push the boundaries of science in the pursuit of effective treatments, the global community eagerly anticipates the outcomes of this promising research. With a focus on enhancing patient care and addressing critical health challenges, Antengene remains at the forefront of the biotech industry, poised to make a lasting impact.